%0 Journal Article %A Andrew D McRae %A Corinne M Hohl %A Rhonda J Rosychuk %A Shabnam Vatanpour %A Gelareh Ghaderi %A Patrick M Archambault %A Steven C Brooks %A Ivy Cheng %A Philip Davis %A Jake Hayward %A Eddy S Lang %A Robert Ohle %A Brian H. Rowe %A Michelle Welsford %A Krishan Yadav %A Laurie J Morrison %A Jeffrey J. Perry %A Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) investigators for the Network of Canadian Emergency Researchers and the Canadian Critical Care Trials Group %T Development and validation of a clinical risk score to predict SARS-CoV-2 infection in emergency department patients: The CCEDRRN COVID-19 Infection Score (CCIS) %D 2021 %R 10.1101/2021.07.15.21260590 %J medRxiv %P 2021.07.15.21260590 %X Objectives To develop and validate a clinical risk score that can accurately quantify an emergency department patient’s probability of SARS-CoV-2 infection without the need for laboratory testingDesign Cohort study of participants in the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) registry. Regression models were fitted to predict a positive SARS-CoV-2 test result using clinical and demographic predictors, as well as an indicator of local SARS-CoV-2 incidence.Setting 32 emergency departments in eight Canadian provincesParticipants 27,665 consecutively-enrolled patients who were tested for SARS-CoV-2 in participating emergency departments between March 1-October 30,2020Main outcome measures Positive SARS-CoV-2 nucleic acid test result within 14 days of an index emergency department encounter for suspected COVID-19 diseaseResults We derived a 10-item CCEDRRN COVID-19 Infection Score using data from 21,743 patients. This score included variables from history and physical examination, and an indicator of local disease incidence. The score had a c-statistic of 0.838 with excellent calibration. We externally validated the rule in 5,295 patients. The score maintained excellent discrimination and calibration, and had superior performance compared to another previously published risk score. Score cutoffs were identified that can rule-in or rule-out SARS-CoV-2 infection without the need for nucleic acid testing with 97.4 % sensitivity (95% CI 96.4–98..3) and 95.9% specificity (95% CI 95.5-96.0).Conclusions The CCEDRRN COVID-19 Infection Score uses clinical characteristics and publicly available indicators of disease incidence to quantify a patient’s probability of SARS-CoV-2 infection. The score can identify patients at sufficiently high risk of SARS-CoV-2 infection to warrant isolation and empiric therapy prior to test confirmation, while also identifying patients at sufficiently low risk of infection that they may not need testing.Trial registration CCEDRRN is registered at clinicaltrials.gov (NCT04702945).Funding The network is funded by the Canadian Institutes of Health Research (447679), BC Academic Health Science Network Society, BioTalent Canada, Genome BC (COV024; VAC007), Ontario Ministry of Colleges and Universities (C-655-2129), the Saskatchewan Health Research Foundation (5357) and the Fondation CHU de Québec (Octroi #4007). These organizations are not-for-profit, and had no role in study conduct, analysis, or manuscript preparation.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicaltrials.gov, NCT04702945Clinical Protocols https://www.cmajopen.ca/content/9/1/E261 Funding StatementThe network is funded by the Canadian Institutes of Health Research (447679), BC Academic Health Science Network Society, BioTalent Canada, Genome BC (COV024; VAC007), Ontario Ministry of Colleges and Universities (C-655-2129), the Saskatchewan Health Research Foundation (5357) and the Fondation CHU de Quebec (Octroi #4007).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Alberta - University of Calgary Conjoint Health Research Ethics Board (REB20-0534); British Columbia - University of British Columbia Clinical Research Ethics Board (H20-01015); Manitoba - University of Manitoba Health Research Ethics Board (H2020:261); New Brunswick - Horizon Health Network Research Ethics Board (100890); Nova Scotia - Nova Scotia Health Authority Research Ethics Board (1025682); Ontario - Queens University Health Sciences & Affiliated Teaching Hospitals Research Ethics Board (2165); Quebec - Centre integre de sante et de services sociaux de Chaudiere-Appalaches(MP-23-2021-766); Saskatchewan - University of Saskatchewan Biomedical Research Ethics Board (1935);All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe CCEDRRN network accepts applications for access to data by external investigators, prioritizing data requests by network Members. https://canadiancovid19ednetwork.org/data-access/ %U https://www.medrxiv.org/content/medrxiv/early/2021/07/22/2021.07.15.21260590.full.pdf